Preferred Label : Givosiran;
NCIt synonyms : RNAi ALN-AS1; RNA Interference Therapeutic ALN-AS1; ESC-GalNAc-siRNA Conjugate ALN-AS1;
NCIt definition : A proprietary enhanced stabilization chemistry (ESC)-stabilized conjugate composed
of the liver-targeted ligand N-acetylgalactosamine (GalNAc) conjugated to small-interfering
RNAs (siRNAs) directed against the liver-expressed enzyme aminolevulinic acid synthase
1 (delta-aminolevulinate synthase 1; ALAS1; ALAS-1) that can potentially be used in
the treatment of acute hepatic porphyrias (AHPs). Upon subcutaneous administration
of givosiran, the GalNAc moiety targets and binds with high affinity to asialoglycoprotein
receptors (ASGPRs) expressed on hepatocytes. Once inside the cell, the siRNAs bind
to and silence ALAS1 mRNA and inhibit both the translation and expression of the ALAS1
protein. This prevents delta-aminolevulinic acid (ALA) formation, decreases 5-ALA
levels and prevents the production of porphyrins and hemes, such as porphobilinogen
(PBG). AHPs are a group of metabolic disorders caused by deficiencies of specific
enzymes that are responsible for hemoglobulin biosynthesis within the liver, which
leads to the accumulation of toxic intermediates, such as ALA and PBG. ALAS1, a liver-expressed,
rate-limiting enzyme in the heme biosynthesis pathway, is responsible for the formation
of ALA from succinyl-CoA and glycine. ESC enables the subcutaneous dosing of givosiran
with increased efficacy, durability and a wide therapeutic index as compared to non-ESC
GalNAc-siRNA conjugates.;
UNII : ROV204583W;
CAS number : 1639325-43-1;
Molecule name : ALN AS1; ALN-AS1;
NCI Metathesaurus CUI : CL544762;
Origin ID : C146805;
UMLS CUI : C4688584;
Automatic exact mappings (from CISMeF team)
Semantic type(s)
UMLS correspondences (same concept)
concept_is_in_subset
https://www.has-sante.fr/jcms/p_3258964/fr/givlaari
2021
false
false
false
France
Givosiran
givosiran
acetylgalactosamine
pyrrolidines
insurance, health, reimbursement
adult
porphyria, acute hepatic
injections, subcutaneous
evaluation of the transparency committee
porphyrias, hepatic
porphobilinogen synthase
porphobilinogen synthase
givosiran
---
https://www.ema.europa.eu/en/medicines/human/EPAR/givlaari
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
Givosiran
Givosiran
acetylgalactosamine
pyrrolidines
acute disease
porphyrias, hepatic
drug approval
europe
product surveillance, postmarketing
adult
adolescent
injections, subcutaneous
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
porphyria, acute hepatic
givosiran
porphobilinogen synthase
porphobilinogen synthase
givosiran
givosiran
---
https://www.has-sante.fr/jcms/p_3191915/fr/givlaari
2020
false
false
false
France
Givosiran
Givosiran
acetylgalactosamine
pyrrolidines
givosiran
injections, subcutaneous
treatment outcome
insurance, health, reimbursement
adult
porphyrias, hepatic
acute disease
porphyria, acute hepatic
guidelines for drug use
continuity of patient care
evaluation of the transparency committee
porphobilinogen synthase
porphobilinogen synthase
givosiran
givosiran
---